ABUS vs LXRX: stock comparison and AI forecast
Arbutus Biopharma Corp (ABUS) and Lexicon Pharmaceuticals, Inc. (LXRX) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
ABUS Arbutus Biopharma Corp
- Market Cap
- $726M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
LXRX Lexicon Pharmaceuticals, Inc.
- Market Cap
- $716M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- ABUS and LXRX have similar market capitalizations ($726M and $716M).
- LXRX carries 0.48 times debt per unit of equity, against 0.06 times for ABUS.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | ABUS | LXRX |
|---|---|---|
| Market Cap | $726M | $716M |
| P/B Ratio | 2.81x | 4.37x |
| EPS | $-0.21 | $-0.13 |
| Book Value/Share | $1.31 | $0.37 |
| Revenue/Share | $0.92 | $0.09 |
Profitability & Margins
| Metric | ABUS | LXRX |
|---|---|---|
| ROE | – | -38.1% |
| ROA | – | -25.8% |
| ROIC | 55.0% | -25.3% |
| Operating Margin | 82.0% | -147.4% |
| Net Margin | – | -161.8% |
| EBT Margin | 84.6% | -147.4% |
| Tax Rate | 0.0% | – |
Financial Health
| Metric | ABUS | LXRX |
|---|---|---|
| Current Ratio | 81.42x | 10.63x |
| Quick Ratio | – | 10.56x |
| D/E Ratio | 0.06x | 0.48x |
| Financial Leverage | 1.06x | 1.48x |
| Interest Coverage | – | -10.5x |
| Working Capital | $271M | $171M |
Cash Flow
| Metric | ABUS | LXRX |
|---|---|---|
| Operating Cash Flow | -$25M | -$49M |
Operational Efficiency
| Metric | ABUS | LXRX |
|---|---|---|
| Asset Turnover | 0.66x | 0.16x |
| Receivables Turnover | 492.5x | 21.7x |
| Inventory Turnover | – | 0.3x |
| Fixed Assets Turnover | 18172.0x | 24.8x |
| Days Sales Outstanding | 1 days | 17 days |
| Days Inventory | – | 1031 days |
| Payables Period | – | 3629 days |
| Cash Conversion Cycle | – | -2581 days |
Income Statement
| Metric | ABUS | LXRX |
|---|---|---|
| Total Revenue | $182M | $39M |
| Operating Income | $149M | -$57M |
| Net Income | – | -$62M |
| R&D Expense | $18M | $58M |
| SG&A Expense | – | $37M |
| Cost of Goods Sold | – | $430K |
Dividend & Shareholder Information
| Metric | ABUS | LXRX |
|---|---|---|
| Shares Outstanding | 198M | 445M |
ABUS vs LXRX: stock comparison and AI forecast
Which is bigger, ABUS or LXRX?
ABUS and LXRX have similar market capitalizations ($726M and $716M).
Which one does Intratio's AI model rank higher, ABUS or LXRX?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.